JAMA Oncol:谢丛华教授发现肿瘤患者感染新冠病毒的风险是普通人群的2.31倍

2020-03-27 张玉辉 医师报

3月25日,国际医学期刊《JAMA Oncology》在线发表了由武汉大学中南医院肿瘤放化疗科谢丛华教授及团队针对肿瘤患者新冠肺炎感染风险的一篇文章

3月25日,国际医学期刊《JAMA Oncology》在线发表了由武汉大学中南医院肿瘤放化疗科谢丛华教授及团队针对肿瘤患者新冠肺炎感染风险的一篇题为《SARS-CoV-2 Transmission in Patients with Cancer at a Tertiary Care Hospital in Wuhan》的回顾性分析。

研究结果显示,暴发城市中的肿瘤患者感染新冠病毒的风险是普通人群的2.31倍。

研究主要分析了2019年12月30日~2020年2月17日在该中心住院的1524例肿瘤患者感染新型冠状病毒肺炎的风险,共纳入12例感染新冠肺炎的肿瘤患者,结果显示,肿瘤患者新冠肺炎感染率为0.79%,高于在数据截止当日武汉市的整体新冠肺炎感染率,肿瘤患者感染新冠肺炎的风险是普通人群的2.31倍。

在本组感染的肿瘤患者中,7例患者为非小细胞肺癌,其中5例正在接受治疗(化疗,化疗±免疫治疗或放疗)。截止至3月10日,12例患者中6例出院,3例仍在接受住院治疗,另外3例患者死亡。

值得注意的是,感染患者中,仅一半不到的患者正在接受抗肿瘤治疗,因此肿瘤治疗导致的免疫抑制在新冠肺炎感染中的作用值得进一步探讨,肿瘤患者定期返院治疗与随诊才是最大的感染风险。

另外,本研究中感染患者的中位年龄为66岁,进一步分析提示:年龄>60岁的患者感染风险可能高于<60岁的患者。

本研究作为疫区内,首篇针对癌症患者感染风险的原创性研究,其结果也再次印证了2020年2月发表的全国的多中心调查的结果,即癌症患者尤其是肺癌患者较普通人群具有更高的感染风险。

由于疫情的持续发展,国内外已有近47万的确诊病例(截止至2020-3-26),越来越多的国家或地区成为新的新冠肺炎爆发地,新冠病毒肺炎目前已经成为全球热门的话题。


本研究在线发表后立即受到国际媒体的普遍关注,研究结果受到多家国外媒体及网络平台转载

谢丛华教授及团队指出,对于肿瘤患者,疫情期间,应该降低返院复查随诊的频率,开展线上随诊;对于一般状况比较好的患者,可适当推迟治疗以减少感染发生的风险;对于需要治疗的患者,必须在适当的隔离条件下进行,以降低SARS-CoV2的感染风险。

该结果为目前正处于疫情暴发过程中的其他国家的肿瘤患者提供了治疗指导。他们希望通过这个研究结果引起社会各界对肿瘤患者的重视,尤其是疫情期间,他们是更需要关注的一群人。

原始出处:

Jing Yu, Wen Ouyang, Melvin L. K. Chua, Conghua Xie. SARS-CoV-2 Transmission in Patients with Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol.2020Mar 25.doi:10.1001/jamaoncol.2020.0980

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1865808, encodeId=cdf61865808fe, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 28 21:32:51 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424313, encodeId=ab95142431376, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sun Mar 29 06:32:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614776, encodeId=f82b1614e7664, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Sun Mar 29 06:32:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027563, encodeId=51e3102e563c5, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Fri Mar 27 18:32:51 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035992, encodeId=6c7e10359923e, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Mar 27 18:32:51 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038008, encodeId=9685103800865, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Fri Mar 27 18:32:51 CST 2020, time=2020-03-27, status=1, ipAttribution=)]
    2020-12-28 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1865808, encodeId=cdf61865808fe, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 28 21:32:51 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424313, encodeId=ab95142431376, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sun Mar 29 06:32:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614776, encodeId=f82b1614e7664, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Sun Mar 29 06:32:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027563, encodeId=51e3102e563c5, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Fri Mar 27 18:32:51 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035992, encodeId=6c7e10359923e, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Mar 27 18:32:51 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038008, encodeId=9685103800865, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Fri Mar 27 18:32:51 CST 2020, time=2020-03-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1865808, encodeId=cdf61865808fe, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 28 21:32:51 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424313, encodeId=ab95142431376, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sun Mar 29 06:32:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614776, encodeId=f82b1614e7664, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Sun Mar 29 06:32:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027563, encodeId=51e3102e563c5, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Fri Mar 27 18:32:51 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035992, encodeId=6c7e10359923e, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Mar 27 18:32:51 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038008, encodeId=9685103800865, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Fri Mar 27 18:32:51 CST 2020, time=2020-03-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1865808, encodeId=cdf61865808fe, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 28 21:32:51 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424313, encodeId=ab95142431376, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sun Mar 29 06:32:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614776, encodeId=f82b1614e7664, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Sun Mar 29 06:32:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027563, encodeId=51e3102e563c5, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Fri Mar 27 18:32:51 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035992, encodeId=6c7e10359923e, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Mar 27 18:32:51 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038008, encodeId=9685103800865, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Fri Mar 27 18:32:51 CST 2020, time=2020-03-27, status=1, ipAttribution=)]
    2020-03-27 公卫新人

    新冠肺炎,疫情何时才能消失

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1865808, encodeId=cdf61865808fe, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 28 21:32:51 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424313, encodeId=ab95142431376, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sun Mar 29 06:32:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614776, encodeId=f82b1614e7664, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Sun Mar 29 06:32:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027563, encodeId=51e3102e563c5, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Fri Mar 27 18:32:51 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035992, encodeId=6c7e10359923e, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Mar 27 18:32:51 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038008, encodeId=9685103800865, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Fri Mar 27 18:32:51 CST 2020, time=2020-03-27, status=1, ipAttribution=)]
    2020-03-27 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1865808, encodeId=cdf61865808fe, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Dec 28 21:32:51 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424313, encodeId=ab95142431376, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Sun Mar 29 06:32:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614776, encodeId=f82b1614e7664, content=<a href='/topic/show?id=b77f59959f2' target=_blank style='color:#2F92EE;'>#普通人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59959, encryptionId=b77f59959f2, topicName=普通人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b9519540847, createdName=ms9476844295372110, createdTime=Sun Mar 29 06:32:51 CST 2020, time=2020-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027563, encodeId=51e3102e563c5, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Fri Mar 27 18:32:51 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035992, encodeId=6c7e10359923e, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Fri Mar 27 18:32:51 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038008, encodeId=9685103800865, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Fri Mar 27 18:32:51 CST 2020, time=2020-03-27, status=1, ipAttribution=)]
    2020-03-27 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

相关资讯

微小转移灶的自发消退:原发性肿瘤分泌物的关键作用

手术切除原发肿瘤是癌症治疗的基石,肿瘤摘除术后转移灶消失的原理,是业界感性去的话题之一。有学者认为,存在于原发性肿瘤的抑制性信号对这一过程起着重要作用。

疫情之下,关注肿瘤患者的治疗与康复

抗肿瘤临床工作中,尤其是在抗击新冠肺炎疫情期间,处理好食疗与药物治疗的关系也很重要。二者都以中医理论为基础,同属于中医治疗恶性肿瘤的方法,相辅相成,不能替代。

JEM:肠道微生物助力CD47抑制剂对抗肿瘤

导读:CD47是肿瘤靶向免疫治疗的基础之一。CD47作为重要的“免疫检查点”分子,在多种肿瘤细胞中广泛过表达,抑制巨噬细胞对肿瘤的吞噬作用

Nature:全新发现一种重要的癌症免疫治疗新方法:Gasdermin E

近期来自波士顿儿童医院发现了癌症免疫疗法的另外一种新武器,可以在更多的癌症类型中发挥作用。这种方法利用人体内免疫反应重新激活称为Gasdermin E的基因,这种基因在许多类型的癌症中均被抑制。

肿瘤中的中位PFS:不能过度迷信,这里也有陷阱

在2019年ESMO上, keynote 407研究更新了最新的结果。在更新的结果中,帕博利珠单抗联合化疗对比安慰剂联合化疗的中位无进展生存(PFS)时间分别为8.0个月对5.1个月,相差近3个月。中

拓展阅读

Anesthesia & Analgesia:基于疫苗接种状态和强制使用口罩的冠状病毒 -2019 疾病相关病例、住院和死亡率的负担: 来自威斯康星州的全州数据和文献叙述性综述

严格遵守公共区域口罩使用和完全接种疫苗状态与改善 COVID-19 相关结果相关,并可减少 COVID-19 的传播、发病率和死亡率。

Pancreatology:COVID-19感染对于急性胰腺炎住院患者的临床结局影响

本项研究证实COVID-19感染和胰腺炎住院患者的住院结局较差,包括脓毒性休克、急性肾损伤和需要血液透析的急性肾损伤发生率增加。

第99届美国神经病理学家协会年会:SARS-CoV-2感染患者死后眼部病理改变

本研究在SARS-CoV-2感染患者的死后眼标本中发现了大量炎症情况。

CGH:接种新冠疫苗可降低新冠阳性的染乳糜泻患者的住院风险

新冠腹泻的机制可能为:病毒进入肠道细胞内复制过程中引发炎症反应,释放促炎因子,增加肠道通透性。

JGH: 艰难梭菌对美国 COVID-19 住院治疗的负担

艰难梭菌(Clostridium difficile,CD)是一种专性厌氧的革兰阳性杆菌,可存在于正常的肠道菌群中,当大量应用广谱抗生素、免疫抑制剂或化疗药物后可导致肠道菌群失调。

Clin Nutr: 一般人群中血浆锌水平与新冠疫苗IgG和IgA血清阳性的关联

疫苗包含特定生物体的弱化或灭活部分(抗原),可在体内引发免疫反应,针对病原体的抗原产生的抗体是免疫系统的重要组成部分。